Randomized, Double-blind [study drug at 25mg, 15 mg or a placebo] Duration: 7 months Study visits: 9 study visits (7 Onsite and 2 telephone visits) Study activities: Blood, Urine and Stool sample collection Complete surveys/questionnaires Eye Exam, ECG Compen...

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy,...

Seizure emergencies involving prolonged seizures are unlikely to stop without treatment, may become more difficult to control with time, and may lead to significant morbidity and mortality. This confirmatory study (EP0162) will investigate the efficacy and safety of a s...

The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (L...

Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous ...

To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.